RxDoctor Payments Data

Charles Bailey, MD

Interventional Cardiology · Austin, TXNPI 1437145174

Payments from drug & device makers

$72,492in general payments, 2019–2025

Across 655 payments — averaging $110.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$24K
  • Boston Scientific$17K
  • Philips North America LLC$13K
  • Penumbra, Inc.$3K
  • Inari Medical, Inc.$2K
  • Abbott$1K
  • plus $12K from 48 others

What the payments were for

  • Consulting fees$6,7459%
  • Speaking & faculty fees$39,00054%
  • Travel & lodging$4,4266%
  • Food & beverage$19,27927%
  • Education$3,0424%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,492 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$147,568
Medicare patients
335
Services billed
1,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$101,719
XareltoRivaroxaban29$37,016
EntrestoSacubitril/Valsartan24$31,547
Repatha SureclickEvolocumab29$23,852
Nebivolol Hcl117$6,497
Valsartan107$3,295
Metoprolol Succinate193$2,636
Ranolazine ErRanolazine13$1,481
Losartan Potassium141$1,458
Nifedipine ErNifedipine44$1,419
ClopidogrelClopidogrel Bisulfate84$1,011
Eplerenone18$820
Potassium Chloride45$802
Flecainide Acetate20$666
Ezetimibe21$649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$368$101,71981 claims
Johnson & JohnsonXarelto$985$37,01629 claims
NovartisEntresto$860$31,54724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →